期刊文献+

Direct-acting Antiviral-induced Transient Recovery of NK Cells in Early-stage Treatment of Chronic Hepatitis C Patients

原文传递
导出
摘要 Background and Aims:The rapid clearance of hepatitis C virus induced by direct-acting antivirals(DAAs)affects natural killer(NK)cells,but the reported results are not consistent,and the relative mechanism was unclear.This study focused on the dynamic changes of NK cells during and after DAA treatment and analyzed the reasons.Meth-ods:Peripheral blood from 35 chronic hepatitis C patients who were treated with DAAs were collected at baseline and weeks 1,2,4,12,and post-treatment week-12.The fre-quency,subset,and phenotype of NK cells were assayed by flow cytometry.Lactate dehydrogenase assays were used to evaluate the cytotoxicity of NK cells.Cytokine concentra-tions were measured with Luminex kits.Results:All pa-tients achieved a sustained viral response(SVR),and the NK cell frequencies were not changed significantly during DAA therapy.However,the cytotoxicity of NK cells recov-ered significantly early in week 1,and then continuously decreased below normal levels.The changes of genotypes including NKp30+,NKp46+,and NKG2A+NK cells were par-allel to NK function.The subset of CD56dim NK cells con-tinuously increased and did not return to normal even at 12 weeks after treatment.Interleukin(IL)-2,IL10,IL15,interferon-gamma,and tumor necrosis factor-alpha all in-creased after week 4,peaked at the end of therapy,and then exhibited varying degrees of reduction with time.Con-clusions:DAA treatment led to transient functional recov-ery of NK cells in the early stage of treatment,and then continuously decreased to below normal levels.Alterations of NK subsets,phenotypes,and the microenvironment may be involved in the changes.
出处 《Journal of Clinical and Translational Hepatology》 SCIE 2022年第6期1117-1124,共8页 临床与转化肝病杂志(英文版)
基金 Beijing Advanced Innova-tion Center for Big Data-based Precision Medicine(No.PXM2021_014226_000026) Special key research pro-ject of capital health development scientific research(No.SF2021-1G-2181) National Natural Science Foundation(No.81500472) Beijing Natural Science Foundation(No.7202070) Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support(No.ZYLX202125).
  • 相关文献

参考文献2

二级参考文献89

  • 1Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK ceil recognition. Immunol Today 1990, 11: 237-244.
  • 2Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol2008, 9: 503-510.
  • 3Orentas R J, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Bio12006, 16: 137-149.
  • 4Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immuno12003, 3: 253-257.
  • 5Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler R l. Galectin-l: a key effector of regulation mediated by CD4+CD25 T cells. Blood2007, 109: 2058-2065.
  • 6Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25 CD4 T cells regulate the expansion of peripheral CD4 T cells through the production of IL-IO. J Immunol 2001, 166: 3008-3018.
  • 7Col lison LW, Workman C J, Kuo TT, Boyd K, Wang Y, Vignali KM et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007: 450: 566-569.
  • 8Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti Jet al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immuno12010, 11:1093-1101.
  • 9Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4CD25+Foxp3 regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immuno12007, 8: 1353-1362.
  • 10Grossman W J, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity2004, 21: 589-601.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部